

UNDER AN EXCEPTIONALLY RARE PRESSURE: PORTAL HYPERTENSION IN MAHVASH DISEASE

Teresa Cadime

UEG Week Berlin 2025

Poster

Pancreas

October 4, 2025

A 54-year-old man with massive pancreatic enlargement was diagnosed with Mahvash disease, a rare genetic disorder caused by GCGR gene variants, presenting with a well-differentiated pancreatic neuroendocrine tumor and subsequent portal hypertension.

KEY POINTS

- Genetic evaluation revealed likely pathogenic variants c.1176+1_1176+7del p.? and c.361T>C p.(Cys121Arg) in the GCGR gene (heterozygous), confirming Mahvash disease, with only about 15 confirmed cases reported to date.
- Biopsy confirmed a well-differentiated (G1) pancreatic neuroendocrine tumor with amyloid stroma; PET/CT with 68Ga-peptides showed focal uptake in the pancreatic tail (SUV max 47.8) and increased uptake throughout the pancreas.
- Treatment was initiated with octreotide and later transitioned to lanreotide.
- Two years later, the patient developed portal hypertension with liver nodules characteristic of hypervascular metastases and large esophageal varices with red spots, which were treated with prophylactic elastic band ligations.
- The case is comprehensively documented through multimodal imaging (CT, PET, MRI, endoscopic ultrasound) and histology, illustrating a rare genetic cause of pancreatic neuroendocrine neoplasm and portal hypertension.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/bc80fc72-a813-11f0-adb3-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.